Latest Hemophilia B Stories
rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding Disorders KING OF PRUSSIA,
-- Using Mutant Protein, CHOP Hematologist Safely Removes Unwanted Antibodies, Reverses Hemophilia in Dog Model of Bleeding Disease -- PHILADELPHIA, March 13, 2015 /PRNewswire-USNewswire/
CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL Behring's Legacy of Improving Patient Well-Being
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B PHILADELPHIA, Dec.
Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and
The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ -
- Large; stout; burly.